T developments in ionization approaches including MALDI-2 and their application as an illustration in redox lipidomics, present an exciting opportunity to study uncommon lipids [726, 727]. In view of the ongoing shift in cancer investigation towards single cell approaches revealing the value of tissue heterogeneity in cancer progression and therapeutic outcome, we’ll witness a shift in the lipidomics field from lipidomics analyses on bulk tissue to single cell and spatial evaluation by mass spectrometry imaging. New technological developments within this domain guarantee an unseen functionality in terms of analytical aspects as well as spatial resolution, top to novel insights inside the part of lipids inside the complicated metabolic interplay in between distinct cell varieties in the heterogenous tumor microenvironment. With novel technologies permitting imaging of lipids at the intracellular level which includes dynamic SIMS ion microcopy and Raman microscopy, a complete new location of lipid analysis is opening up, revealing changes in organellar lipidomes, trafficking pathways and membrane structures [728, 729]. The further development of steady isotope lipidomics will enable to stick to changes in pathway fluxes as an alternative of existing steady state evaluation and collectively with spatial multi-omics approaches will give unprecedented insight in impacted pathways and CB2 MedChemExpress possible biomarkers. Together with these developments there is certainly an urgent need for standardization of techniques and technologies to let future clinical implementations from the found biomarkers. In terms of therapeutic possible, current findings recommend that interference with lipid metabolism may have promising applications, specifically in combinatorial approaches. With small molecules targeting enzymes in lipid metabolism getting into clinical trials we are in the doorstep of witnessing the clinical exploitation of altered lipid metabolism as a hallmark of cancer. The link with the diet, such as dietary lipids may also build unique opportunities for preventive methods and therapy enhancement. Specifically within the field of tumor immunology, lipids hold fantastic potential as modulators. In summary, while lagging behind when compared with other omics approaches, the study of lipids in cancer is quickly catching up and is establishing itself as a central hallmark of cancer with promising possibilities for clinical application.Author Manuscript Author Manuscript Author Manuscript Funding Author ManuscriptThis function was supported by an EU Interreg grant V-A EMR23 EURLIPIDS, KU Leuven grants C1 (C16/15/073) and C3 (C32/17/052), Investigation Foundation-Flanders (FWO), Stichting tegen Kanker, Kom op tegen Kanker, the Movember Foundation/Prostate Cancer Foundation of Australia (MRTA3), The Prostate Cancer Foundation of Australia (ID NDDA), the Cancer Council South Australia Beat Cancer Project, NIH grant RO1CA58961, a Norris Cotton Cancer Center grant, plus the Dartmouth College Norris Cotton Cancer Center Help Grant P30CA023108. ML’s operate is supported by NIH grants MAO-B list RO1CA131945, R01CA187918, DoD PC160357, DoD PC180582, P50CA211024, plus the Prostate Cancer Foundation.AbbreviationsAA ACACA arachidonic acid acetyl-CoA carboxylase alphaAdv Drug Deliv Rev. Author manuscript; offered in PMC 2021 July 23.Butler et al.PageACACBacetyl-CoA carboxylase beta ATP-citrate lyase Acyl-CoA Synthetase acylprotein thioesterase androgen receptor acid sphingomyelinase adipose triglyceride lipase autotaxin breast cancer clear cell renal cell carcinoma chol.